Ziihera plus tislelizumab and chemotherapy approved for first-line treatment of all HER2+ GEA patients (IHC 3+ and IHC 2+/ISH+) regardless of PD-L1 status, providing a new treatment option in front-......
FORT WASHINGTON, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Coventry, the leader and creator of the secondary market for life insurance and a pioneer of the life insurance-backed asset class, today announ......
